Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS). The American Urological Association.
about
Bacillus Calmette-Guérin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literatureMolecular markers in transitional cell carcinoma of the bladder: New insights into mechanisms and prognosisOptimal management of high-risk T1G3 bladder cancer: a decision analysisUrotensin II receptor determines prognosis of bladder cancer regulating cell motility/invasion.Herpes simplex virus based gene therapy enhances the efficacy of mitomycin C for the treatment of human bladder transitional cell carcinomaTumour growth inhibition by an imidazoquinoline is associated with c-Myc down-regulation in urothelial cell carcinoma.Urologist referral delay and its impact on survival after radical cystectomy for bladder cancerGenetic susceptibility to bladder cancer risk and outcome.Best practice in the treatment of nonmuscle invasive bladder cancer.Predictors of intravesical therapy for nonmuscle invasive bladder cancer: results from the surveillance, epidemiology and end results program 2003 patterns of care project.Is intravesical chemotherapy for superficial bladder cancer still justified?The management of superficial transitional cell carcinoma of the bladder: a critical assessment of contemporary concepts and future perspectives.Intravenous chemotherapy combined with intravesical chemotherapy to treat T1G3 bladder urothelial carcinoma after transurethral resection of bladder tumor: results of a retrospective studyPaclitaxel gelatin nanoparticles for intravesical bladder cancer therapyBacillus Calmette-Guérin in the management of superficial bladder cancer.Quality of care in bladder cancer: trends in urinary diversion following radical cystectomy.Treatment of nonmuscle invading bladder cancer: do physicians in the United States practice evidence based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors.Economic aspects of bladder cancer: what are the benefits and costs?Prophylactic effects of Bacille Calmette-Guérin intravesical instillation therapy: time period-related comparison between Japan and Western countriesIntravesical therapy for urothelial carcinoma of the bladder.Survival after primary and deferred cystectomy for stage T1 transitional cell carcinoma of the bladder.Photodynamic diagnosis for superficial bladder cancer: do all risk-groups profit equally from oncological and economic long-term results?Predictive factors for residual tumor and tumor upstaging on relook transurethral resection of bladder tumor in non-muscle invasive bladder cancer.Next-generation sequencing in non-muscle-invasive bladder cancer-a step towards personalized medicine for a superficial bladder tumor.
P2860
Q27021357-D13FD02A-5597-437E-AB08-F427E8CAA7EAQ30439612-D5334071-97DA-4BFD-8A6A-F69878CCE46DQ33300413-E4BD5C9D-E50C-48EE-9E4E-A6EAD6FD6980Q33772333-10C90F64-6C6A-4C63-BF8A-5F4BEAB1FD33Q34313378-2B522BD8-2666-4650-8BB3-D442C85FE6F2Q34744159-C838267A-F577-4413-BB51-4158F0A7ABE6Q35072460-17E69371-57A4-4EE9-8EAD-4EE63ABDE1BFQ35212792-30724BEF-54F4-4606-9DE8-A40844ED948CQ35688392-E6479302-12F6-490F-99F7-8C62674A936FQ35891583-91315493-D74E-4526-8B92-021EA0E59B0EQ36253605-AF9767BF-A440-4343-A59A-E4F4B83DFE94Q36312232-AA8B5067-0E93-47A7-B239-747556ABC049Q36525727-3D10F6A7-E1CE-448A-862F-99572B178AEDQ36848145-181AD735-4B84-4B5F-8F66-0118058FFE4DQ37197525-4DB0E47F-0445-42CF-AA8F-238BFB1F7061Q37261045-7A263E64-AA72-4AFB-8C87-355B9C90A4D4Q37403151-6B0A4DE9-FE7C-4BEE-A778-7DD69E892230Q37409352-2EA52187-061A-44EC-B456-5AC988536E86Q37471721-2439333C-667B-4929-BE09-AE1DCD7BE86BQ37911278-85AE286B-EF43-4EC6-B34A-B2AB479CE7B1Q38597091-4519E5A5-BD94-41CE-92C2-EC106E2A0B5BQ40636192-A220A458-5225-443C-B100-38D7FE832017Q42971182-7686B249-4CC7-4260-84D1-0CA1AB11CBEAQ49206807-658CF4F7-4FC5-4E2A-A17B-80EE4CD1E728
P2860
Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS). The American Urological Association.
description
1999 nî lūn-bûn
@nan
1999 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Bladder cancer clinical guidel ...... erican Urological Association.
@ast
Bladder cancer clinical guidel ...... erican Urological Association.
@en
type
label
Bladder cancer clinical guidel ...... erican Urological Association.
@ast
Bladder cancer clinical guidel ...... erican Urological Association.
@en
prefLabel
Bladder cancer clinical guidel ...... erican Urological Association.
@ast
Bladder cancer clinical guidel ...... erican Urological Association.
@en
P2093
P1476
Bladder cancer clinical guidel ...... erican Urological Association.
@en
P2093
Cockett AT
Fracchia JA
Labasky RF
Rowland RG
Smith JA Jr
P304
P356
10.1097/00005392-199911000-00040
P407
P577
1999-11-01T00:00:00Z